The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeutics’ antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. 

A humanised anti-CD117 monoclonal antibody, JSP191 hinders stem cell factor receptor signalling, resulting in hematopoietic stem and progenitor cell clearance from the bone marrow.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Currently in the clinical stage, the antibody is being developed as a stem cell transplant conditioning agent. It aids in creating a vacant space for the donor or gene-corrected transplanted stem cells to be engrafted. 

In an ongoing multicentre clinical trial, JSP191 has so far been analysed in 14 patients with SCID.

The antibody was also analysed in a total of more than 110 healthy subjects and patients. 

See Also:

Jasper Therapeutics president and CEO Ronald Martell said: “Patients born with SCID have a severely compromised immune system and need to rely on an allogeneic hematopoietic stem cell transplant to create the immune cells needed to fight infection. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Along with the FDA’s previous designations of Orphan and Rare Pediatric Disease for JSP191, this new Fast Track designation recognises the potential role of JSP191 in improving clinical outcomes for these patients and will allow us to more closely work with the FDA in the upcoming months to determine a path toward a Biologics License Application (BLA) submission.”

Apart from SCID, three other trials of JSP191 for myelodysplastic syndromes (MDS)/ acute myeloid leukaemia (AML), Fanconi anaemia (FA) and sickle cell disease undergoing allogeneic transplant are progressing. 

The company plans to advance the antibody to clinics as a second-line therapy in transfusion-dependent, reduced-risk MDS patients later in the year.